SANGAMO THERAPEUTICS, INC 8-K/A

What Happened Sangamo Therapeutics filed a Form 8-K on June 23, 2026 disclosing that it entered into two asset purchase agreements dated June 22, 2026. One agreement (Exhibit 2.1) involves Merope Acquisition Sub, LLC and Eli Lilly and Company and covers certain Sangamo affiliates (Sangamo Therapeutics UK Ltd., Sangamo Therapeutics France SAS, and Ceregene, Inc.). The second agreement (Exhibit 2.2) is with Astellas Gene Therapies, Inc. The 8-K attaches those agreements as exhibits but does not disclose purchase prices or other material financial terms in this filing.

Key Details

• Agreements dated June 22, 2026 and disclosed in Form 8-K filed June 23, 2026 (Exhibits 2.1 and 2.2).
• Counterparties: Eli Lilly and Company (via Merope Acquisition Sub, LLC) and Astellas Gene Therapies, Inc.
• Certain exhibits and schedules to the agreements were omitted under Regulation S‑K Item 601(a)(5); Sangamo will furnish omitted materials to the SEC upon request.
• The filing includes the Cover Page Interactive Data File (Inline XBRL) and is signed by Scott B. Willoughby, Chief Legal Officer, on behalf of Sangamo.

Why It Matters These filings confirm Sangamo has entered into asset sale transactions with major biopharma buyers (Eli Lilly and Astellas). The 8-K does not provide financial terms or details on which assets are being sold beyond the named affiliates, so investors should watch for follow-up disclosures (additional 8‑Ks, press releases, or SEC filings) that describe purchase price, closing conditions, and the expected impact on Sangamo’s operations and financial results.